BackAllogene Therapeutics Overview

Allogene Therapeutics Current Cash

Track Allogene Therapeutics's current cash ($39M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$38.63M
↓ 26.19% YoYΔ $-13.71M vs prior year quarter

Peer trimmed avg / median

Loading

Allogene Therapeutics Current Cash History

Loading

Allogene Therapeutics vs. peers: Current Cash Comparison

Loading

Allogene Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Allogene Therapeutics (ALLO) FAQ

As of the most recent data (June 2026), ALLO shows a current cash of $39M. That compares with $52M in the prior-year period — down 26.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALLO's current cash is now $39M (was $52M) — a 26.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Allogene Therapeutics is outperforming or lagging.

Tracking ALLO's current cash over time shows whether Allogene Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $39M That compares with $52M in the prior-year period — down 26.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Allogene Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $39M) with ownership activity and broader fundamentals.

Allogene Therapeutics's current cash is $39M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.